Xencor, Inc. (NASDAQ:XNCR) is scheduled to release its earnings data after the market closes on Monday, July 31st. Analysts expect Xencor to post earnings of ($0.28) per share for the quarter.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.06. The firm had revenue of $4.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a net margin of 18.19% and a return on equity of 5.98%. On average, analysts expect Xencor to post $-1.14 EPS for the current fiscal year and $-1.62 EPS for the next fiscal year.
Xencor, Inc. (XNCR) opened at 23.665 on Friday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 67.040 and a beta of 2.13. The stock has a 50 day moving average price of $22.21 and a 200-day moving average price of $23.17. Xencor, Inc. has a one year low of $18.45 and a one year high of $29.38.
COPYRIGHT VIOLATION WARNING: This article was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/07/30/xencor-inc-xncr-scheduled-to-post-earnings-on-monday.html.
In other news, Director Bruce L. A. Carter sold 12,400 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $22.19, for a total transaction of $275,156.00. Following the sale, the director now owns 83,344 shares of the company’s stock, valued at approximately $1,849,403.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 10,568 shares of the business’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total value of $274,873.68. Following the sale, the insider now directly owns 9,818 shares in the company, valued at approximately $255,366.18. The disclosure for this sale can be found here. Insiders have sold a total of 45,334 shares of company stock worth $1,014,282 in the last quarter. 4.03% of the stock is currently owned by insiders.
XNCR has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $29.00 price target on shares of Xencor in a research report on Friday, June 16th. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $28.67.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
